Cargando…

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

OBJECTIVE: Value frameworks in oncology have not been validated for the assessment of treatments in haematological malignancies, but to avoid overlaps and duplications it appears reasonable to build up experience on existing value frameworks, such as the European Society for Medical Oncology—Magnitu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kiesewetter, Barbara, Cherny, Nathan I, Boissel, Nicolas, Cerisoli, Francesco, Dafni, Urania, de Vries, Elisabeth G E, Ghia, Paolo, Gökbuget, Nicola, González-Calle, Verónica, Huntly, Brian, Jäger, Ulrich, Latino, Nicola Jane, Douillard, Jean-Yves, Malcovati, Luca, Mateos, María-Victoria, Ossenkoppele, Gert J, Porkka, Kimmo, Raderer, Markus, Ribera, Josep-Maria, Scarfò, Lydia, Wester, Ruth, Zygoura, Panagiota, Sonneveld, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003483/ https://www.ncbi.nlm.nih.gov/pubmed/31958292 http://dx.doi.org/10.1136/esmoopen-2019-000611

Ejemplares similares

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
por: Paluch-Shimon, Shani, et al.
Publicado: (2020)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

EHA Endorsement of ESMO Clinical Practice Guidelines for Marginal Zone Lymphomas
por: Ladetto, Marco, et al.
Publicado: (2020)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Follicular Lymphoma
por: Ladetto, Marco, et al.
Publicado: (2021)

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
por: Dimopoulos, Meletios A., et al.
Publicado: (2021)

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
por: Buske, C., et al.
Publicado: (2022)

ESMO 2017—my personal highlights
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS
por: Ha, Hyerim, et al.
Publicado: (2022)

Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS
por: Jiang, Qian, et al.
Publicado: (2020)

EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma
por: Linton, Kim, et al.
Publicado: (2020)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Waldenström’s Macroglobulinemia
por: Staber, Philipp B., et al.
Publicado: (2021)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes
por: van de Loosdrecht, Arjan A., et al.
Publicado: (2022)

ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award
por: Cherny, Nathan I
Publicado: (2016)

EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia
por: Eichhorst, Barbara, et al.
Publicado: (2020)

Correction Notice: Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Publicado: (2021)

Correction Notice: Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Publicado: (2021)

ESMO Copenhagen 2016: a lung cancer ‘grand cru’
por: Douillard, Jean-Yves
Publicado: (2017)

Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care
por: Hui, David, et al.
Publicado: (2018)

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
por: Dreyling, Martin, et al.
Publicado: (2021)

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
por: van Halteren, H.K., et al.
Publicado: (2022)

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
por: Banerjee, Susana, et al.
Publicado: (2018)

Corrigendum to ‘How I treat medullary thyroid cancer’: [ESMO Open Volume 6, Issue 3, June 2021, 100183]
por: Kiesewetter, B., et al.
Publicado: (2022)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

1777P Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS
por: Aboelhassan, R.A.M., et al.
Publicado: (2020)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer
por: Catanese, Silvia, et al.
Publicado: (2020)

My personal highlights of ESMO 2016
por: Dediu, M., et al.
Publicado: (2017)

Pain workshop ESMO: Africa (response)
por: Grant, Liz, et al.
Publicado: (2020)

ESMO 2021—highlights in colorectal cancer
por: Weiss, Lukas
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ejm6mci8sf9br87c4semn2pikm